HIV envelope polypeptides and immunogenic composition
AssigneeGenentech, Inc.
InventorPhillip W. Berman
Life of this patent
Estimating the term…
Abstract
Oligonucleotide sequences encoding gp120 polypeptides from breakthrough isolates of vaccine trials using MN-rgp120 and the encoded gp120 polypeptides are provided. Use of the gp120 polypeptides from one or more of the isolates in a subunit vaccine, usually together with MN-rgp120, can provide protection against HIV strains that are sufficiently different from the vaccine strain (e.g.; MN-rgp120) that the vaccine does not confer protection against those strains. Antibodies induced by the polypeptides are also provided.
Claims14
An immunogenic composition comprising a first polypeptide comprising a gp120 MN sequence as identified by Sequence ID No. 41, or a fragment thereof, and a polypeptide comprising a breakthrough isolate gp120 sequence selected from the group consisting of Sequence ID Nos. 2, 5, 8, 10, 12, 16, 19, 23, 25, 28, 31, 33, 36, 39, and fragments thereof, in a suitable carrier, wherein each of said fragments comprises at least the V2, V3, and C4 domains of gp120.
An immunogenic composition comprising:
- a) a first polypeptide comprising a first gp120 sequence or a fragment thereof;
- and
- b) a polypeptide comprising a breakthrough isolate gp120 sequence, or a fragment thereof, wherein said breakthrough isolate gp120 sequence is selected from the group consisting of Sequence ID Nos. 2, 5, 8, 10, 12, 16, 19, 23, 25, 28, 31, 33, 36, and 39;
- wherein each of said fragments comprises at least the V2, V3, and C4 domains of gp120, and said polypeptides are in a suitable carrier.
A method for making an improved HIV immunogenic composition comprising:
- a) providing a first immunogenic composition comprising a first polypeptide comprising a first gp120 sequence or a fragment thereof;
- b) obtaining a breakthrough isolate from an individual immunized with said first polypeptide;
- c) selecting a breakthrough isolate gp120 sequence, or a fragment thereof, from said breakthrough isolate;
- and
- d) adding a polypeptide comprising said breakthrough isolate gp120 sequence, or fragment thereof, to said first immunogenic composition;
- wherein each of said fragments comprises at least the V2, V3, and C4 domains of gp120.
Dependencies are inferred from the claim text.